Park Avenue Securities LLC increased its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO – Free Report) by 28.2% during the ...

Bio-Rad Laboratories, Inc.’s BIO solid momentum in the QX600 Droplet Digital PCR (ddPCR) platform is poised to help it grow in the upcoming quarters. The clinical diagnostics business sees increased ...

Gateway Investment Advisers LLC raised its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO – Free Report) by 47.5% during the ...

S&P 500 Shake-Up: New Entrants Driving Market Momentum The S&P 500 is a widely recognized benchmark for the US stock market, and it has undergone reshuffling due to the quarterly rebalancing process.

RBC Capital analyst Conor McNamara maintained a Buy rating on Bio-Rad Laboratories (BIO – Research Report) today and set a price target of ...

Geneoscopy Closes $105M in Series C Funding Round to Power Next-Generation of Gastrointestinal Diagnostic Tests Bio-Rad leads investment to support the launch of ColoSense ®, a non-invasive colorectal ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...